Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity
Cumberland Pharmaceuticals Inc. has transformed from a commercial-stage pharma to a pre-revenue, Phase 2-stage biotech focused on rare diseases. Recent $100M asset sale to Apotex funds operations and pipeline, with a special dividend paid to shareholders and four late-stage clinical programs retained. All pipeline assets are based on ifetroban, targeting high-value indications like DMD cardiomyopathy, cancer metastasis, systemic sclerosis, and IPF.
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript
Cumberland Pharmaceuticals Q2 Earnings Call Highlights
Cumberland Pharmaceuticals NASDAQ: CPIX reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business following the sale of its branded U.S. commercial portfolio to Apotex Health.
Cumberland Pharmaceuticals Inc. (CPIX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cumberland Pharmaceuticals Inc. ever had a stock split?
Cumberland Pharmaceuticals Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | A. J. Kazimi CEO | NASDAQ (NGS) Exchange | 230770109 CUSIP |
| US Country | 88 Employees | 3 Aug 2026 Last Dividend | - Last Split | 11 Aug 2009 IPO Date |
Overview
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company with a focus on acquiring, developing, and commercializing prescription products targeted at hospital acute care, gastroenterology, and oncology sectors both in the United States and internationally. Since its incorporation in 1999 and with headquarters in Nashville, Tennessee, the company has been committed to addressing the needs of patients with serious or underserved medical conditions through its diverse portfolio of approved products and candidates in development.
Products and Services
- Acetadote - An injectable product designed for the treatment of acetaminophen poisoning, helping to mitigate potentially life-threatening conditions resulting from overdose.
- Caldolor - An injection used for the treatment of pain and fever, providing an alternative route of administration for patients unable to use oral forms of medication.
- Kristalose - A prescription oral solution acting as a laxative for the treatment of constipation, offering a therapeutic option for patients with this condition.
- Omeclamox-Pak - Designed for the treatment of Helicobacter pylori infection and duodenal ulcer disease, this product aims to eradicate H. pylori bacteria, known to cause peptic ulcers.
- Vaprisol - An injectable solution for treating euvolemic and hypervolemic hyponatremia, addressing electrolyte imbalance in the body.
- Sancuso - An injection provided for the management of side effects caused by chemotherapy treatments, specifically to control nausea and vomiting.
- Vibativ - An injection formulated for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
- RediTrex - Currently under development, this injectable medication is aimed at treating active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and disabling psoriasis.
In addition to these products, Cumberland Pharmaceuticals is actively engaged in the development of ifetroban, a versatile product candidate undergoing phase II clinical trials for various conditions, including aspirin-exacerbated respiratory disease, systemic sclerosis, Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and progressive fibrosing interstitial lung diseases.
Contact Information
